Dr Susan Bal speaks to ecancer about guiding transplant decisions in multiple myeloma with MRD.

The MILESTONE trial explores how minimal residual disease (MRD) can guide transplant decisions for multiple myeloma patients.

MRD serves as a key prognostic marker, with the FDA endorsing it for therapy approval.

The study involved six cycles of quadruplet induction therapy, leading to significant MRD negativity rates among 20 patients.

Long-term follow-up is crucial to evaluate the sustainability of these responses, and a cohort on AL amyloidosis is also included.